Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.38 |
| ▸ | TUBB | P07437 | 4/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.38 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.38 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.38 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.38 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.38 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.38 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.38 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15010996 | 1.00 | AR (0.51) | ARENPP2CYP11B2CYP11B1SLC6A4 | |
| SCHEMBL1303073 | 0.85 | AR (0.49) | ARENPP2CYP11B2CYP11B1SLC6A4 | |
| SCHEMBL22717679 | 0.85 | AR (0.46) | ARENPP2CYP11B2CYP11B1SLC6A4 | |
| SCHEMBL31314173 | 0.81 | ENPP2 (0.47) | ARENPP2TUBB4ATUBBTUBA3C | |
| SCHEMBL31019037 | 0.79 | AR (0.53) | ARENPP2CYP11B2CYP11B1SLC6A4 | |
| SCHEMBL29490258 | 0.78 | AR (0.66) | ARCYP11B2CYP11B1SLC6A4EGLN2 | |
| SCHEMBL509522 | 0.78 | AR (0.66) | ARCYP11B2CYP11B1SLC6A4EGLN2 | |
| SCHEMBL1614452 | 0.77 | AR (0.40) | ARENPP2EGLN2TUBB4ATUBB | |
| SCHEMBL29804271 | 0.77 | MAOB (0.55) | AR | |
| SCHEMBL459931 | 0.77 | MAOB (0.55) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4609865-A2 | NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4337652-B1 | NLRP3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2025-04-09 | — | — | EP | disclosed |
| CN-119060098-A | Organic electroluminescent material and device | 环球展览公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-4433459-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | F. Hoffmann-La Roche AG (CH) | 2024-09-25 | — | — | EP | disclosed |
| CN-118525025-A | Six-membered cyclothiazole compound and application thereof | 南京再明医药有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20240208928-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024094150-A1 | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023088987-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-25 | — | — | WO | disclosed |
| EP-4118136-A1 | DYNAMIC COVALENT HYDROGELS, PRECURSORS THEREOF AND USES THEREOF | Centre National de la Recherche Scientifique (CNRS) (FR) | 2023-01-18 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208928-A1 | NOVEL COMPOUNDS | RB1, RPS4X, RPS4Y1 | AR 193/4885ENPP2 1445/4885CYP11B2 34/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | AR 1849/4885ENPP2 548/4885CYP11B2 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.